Time point | EM N (%) | DISS N (%) | Controls N (%) | EM vs. controls | DISS vs. controls | ||
---|---|---|---|---|---|---|---|
RR (95% CI) | P-value | RR (95% CI) | P-value | ||||
Total N | |||||||
6 months | 120 | 15 | 128 | ||||
12 months | 94 | 11 | 81 | ||||
PTLDS-related symptomsa | |||||||
Muscle pain | |||||||
6 months | 11 (9.2) | 2 (13.3) | 3 (2.3) | 3.91 (1.11–13.77) | 0.034 | 5.69 (1.02–31.84) | 0.048 |
12 months | 7.4 (7.9) | 0 (0) | 1 (1.2) | 6.36 (0.79–51.27) | 0.082 | 0 (0–Inf) | 0.997 |
Joint pain | |||||||
6 months | 7 (5.8) | 5 (33.3) | 4 (3.1) | 1.87 (0.56–6.25) | 0.310 | 10.67 (3.18–35.83) | < 0.001 |
12 months | 11.6 (12.3) | 4 (36.4) | 6 (7.4) | 1.66 (0.64–4.29) | 0.296 | 4.91 (1.61–14.93) | 0.006 |
Fatigue | |||||||
6 months | 15.2 (12.7) | 5 (33.3) | 4 (3.2) | 4.02 (1.36–11.86) | 0.012 | 10.55 (3.14–35.44) | < 0.001 |
12 months | 8 (8.5) | 5 (45.5) | 3 (3.7) | 2.30 (0.62–8.45) | 0.209 | 12.27 (3.33–45.17) | < 0.001 |
Memory difficulties | |||||||
6 months | 6 (5.0) | 0 (0) | 3 (2.3) | 2.13 (0.54–8.40) | 0.277 | 0 (0–Inf) | 0.995 |
12 months | 6 (6.4) | 0 (0) | 2 (2.5) | 2.59 (0.53–12.60) | 0.238 | 0 (0–Inf) | 0.996 |
Concentration difficulties | |||||||
6 months | 4 (3.3) | 0 (0) | 1 (0.8) | 4.27 (0.48–38.05) | 0.193 | 0 (0–Inf) | 0.997 |
12 months | 5 (5.3) | 1 (9.1) | 0 (0.0) | Inf (0–Inf) | 0.992 | Inf (0–Inf) | 0.997 |
Wording difficulties | |||||||
6 months | 2 (1.7) | 0 (0) | 4 (3.1) | 0.53 (0.10–2.88) | 0.464 | 0 (0–Inf) | 0.995 |
12 months | 4 (4.3) | 1 (9.1) | 1 (1.2) | 3.45 (0.39–30.69) | 0.265 | 7.36 (0.48–113.68) | 0.151 |
Other symptomsb | |||||||
Headache | |||||||
6 months | 5 (4.2) | 0 (0) | 2 (1.6) | 2.67 (0.52–13.59) | 0.237 | 0 (0–Inf) | 0.995 |
12 months | 3 (3.2) | 0 (0) | 2 (2.5) | 1.29 (0.22–7.64) | 0.776 | 0 (0–Inf) | 0.996 |
Sensory disorders | |||||||
6 months | 7 (5.8) | 1 (6.7) | 1 (0.8) | 7.47 (0.92–60.37) | 0.059 | 8.53 (0.55–132.63) | 0.125 |
12 months | 3 (3.2) | 0 (0) | 0 (0.0) | Inf (0–Inf) | 0.995 | 1.00 (0–Inf) | > 0.999 |
Night sweats | |||||||
6 months | 3 (2.5) | 0 (0) | 3 (2.3) | 1.07 (0.22–5.22) | 0.936 | 0 (0–Inf) | 0.995 |
12 months | 2 (2.1) | 0 (0) | 6 (7.4) | 0.29 (0.06–1.40) | 0.122 | 0 (0–Inf) | 0.993 |
Excessive sleeping | |||||||
6 months | 5 (4.2) | 0 (0) | 3 (2.3) | 1.78 (0.43–7.33) | 0.424 | 0 (0–Inf) | 0.995 |
12 months | 3 (3.2) | 0 (0) | 2 (2.5) | 1.29 (0.22–7.64) | 0.776 | 0 (0–Inf) | 0.996 |
Difficulties falling asleep | |||||||
6 months | 2 (1.7) | 1 (6.7) | 5 (3.9) | 0.43 (0.08–2.21) | 0.312 | 1.73 (0.21–14.13) | 0.609 |
12 months | 4.8 (5.0) | 0 (0) | 3 (3.7) | 1.36 (0.32–5.74) | 0.675 | 0 (0–Inf) | 0.996 |
Swollen joints | |||||||
6 months | 2.3 (1.9) | 1 (6.7) | 2 (1.6) | 1.20 (0.17–8.40) | 0.850 | 4.27 (0.40–45.22) | 0.226 |
12 months | 2 (2.1) | 0 (0) | 3 (3.7) | 0.57 (0.10–3.40) | 0.539 | 0 (0–Inf) | 0.996 |